Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C3AR1 | Q16581 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805171 | 0.93 | C3AR1 (0.40) | C3AR1MAPTSUCNR1TDP1ATM | |
| SCHEMBL10045827 | 0.91 | C3AR1 (0.41) | C3AR1MAPTSUCNR1TDP1ATM | |
| SCHEMBL801069 | 0.88 | C3AR1 (0.40) | C3AR1MAPTSUCNR1TDP1ATM | |
| SCHEMBL800465 | 0.85 | C3AR1 (0.37) | C3AR1 | |
| SCHEMBL10045826 | 0.84 | C3AR1 (0.39) | C3AR1MAPTSUCNR1TDP1ATM | |
| SCHEMBL805233 | 0.84 | MAOA (0.36) | C3AR1MAPTTDP1ATMNPSR1 | |
| SCHEMBL800483 | 0.81 | C3AR1 (0.42) | C3AR1MAPTATMNPSR1MEN1 | |
| SCHEMBL800475 | 0.81 | C3AR1 (0.38) | C3AR1MAPTSUCNR1TDP1ATM | |
| SCHEMBL10045819 | 0.79 | MAPT (0.52) | C3AR1MAPTTDP1NPSR1POLB | |
| SCHEMBL800524 | 0.78 | C3AR1 (0.34) | C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093235-B2 | Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093235-B2 | Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-18 | — | — | US | disclosed |
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, RECQL | C3AR1 2510/4885MAPT 1974/4885SUCNR1 3565/4885 |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | C3AR1 2841/4885MAPT 2056/4885SUCNR1 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.